| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Mar 10, 201324-Month Clinical Update from Symplicity HTN-2 Presented Today at the 62nd Annual Scientific Session of the American College of Cardiology
MINNEAPOLIS and SAN FRANCISCO - March 10, 2013 - Medtronic, Inc. (NYSE: MDT) today announced 24-month data from Symplicity HTN-2, the first randomized clinical trial investigating renal...
-
Mar 7, 2013IDE Submission for Symplicity HTN-4 Expands the Indicated Patient Population and Builds upon Medtronic's Rigorous Global Clinical Trial Program for Hypertension Treatment
MINNEAPOLIS - March 7, 2013 - Medtronic, Inc. (NYSE: MDT), announced today that the company has submitted an Investigational Device Exemption (IDE) to the U.S. Food and Drug Administration (FDA)...
-
Mar 6, 2013FDA-CMS Parallel Review Program Designed to Enable Efficient and Earlier Patient Access to Innovative Medical Advancements
MINNEAPOLIS - March 6, 2013 - Medtronic, Inc. (NYSE: MDT) today announced the U.S. Food and Drug Administration (FDA)and the Centers for Medicare & Medicaid Services (CMS) have accepted the...
-
Dec 17, 2012Published data demonstrate the Symplicity(TM) renal denervation system provides blood pressure reduction in patients with treatment-resistant hypertension sustained to 12 months
MINNEAPOLIS - December 17, 2012 - Medtronic, Inc. (NYSE: MDT) today announced that one-year results from Symplicity HTN-2, the first randomized clinical trial investigating renal denervation, were...
-
Sep 12, 2012Findings Published in The Journal of the American College of Cardiology Suggest Renal Denervation Could Substantially Reduce Cardiovascular Morbidity and Mortality for Patients with a Condition that Affects 120 Million People
MINNEAPOLIS - September 12, 2012 - Medtronic, Inc. (NYSE: MDT) today announced findings from a health-economic analysis published online before print in The Journal of the American College of...